Urinary melatonin levels and breast cancer risk

Journal of the National Cancer Institute

Volumn 97, Issue 14, 2005, Pages 1084-1087

  Schernhammer, Eva S ^a,b,c   Hankinson, Susan E ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

MELATONIN; SEX HORMONE; 6 HYDROXYMELATONIN O SULFATE; 6-SULFATOXYMELATONIN; DRUG DERIVATIVE;

ADULT; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER RISK; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; METABOLITE; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL MODEL; URINE LEVEL; AGED; BREAST TUMOR; INCIDENCE; MIDDLE AGED; NURSE; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; RISK; RISK FACTOR; STATISTICS; UNITED STATES; URINE;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; FEMALE; HUMANS; INCIDENCE; LOGISTIC MODELS; MELATONIN; MIDDLE AGED; NURSES; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 23244435107     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dji190     Document Type: Article

References (39)

1. Czeisler CA, Klerman EB. Circadian and sleep-dependent regulation of hormone release in humans. Recent Prog Horm Res 1999; 54:97-130.
2. Czeisler CA, Duffy JF, Shanahan TL, Brown EN, Mitchell JF, Rimmer DW, et al. Stability, precision, and near-24-hour period of the human circadian pacemaker. Science 1999;284:2177-81.
3. Arendt J. Melatonin and the pineal gland: Influence on mammalian seasonal and circadian physiology. Rev Reprod 1998;3:13-22.
4. Zeitzer JM, Dijk DJ, Kronauer R, Brown EN, Czeisler C. Sensitivity of the human circadian pacemaker to nocturnal light: Melatonin phase resetting and suppression. J Physiol 2000;526:695-702.
5. Leibenluft E, Feldman-Naim S, Turner EH, Schwartz PJ, Wehr TA. Salivary and plasma measures of dim light melatonin onset (DLMO) in patients with rapid cycling bipolar disorder. Biol Psychiatry 1996;40: 731-5.
6. Nowak R, McMillen IC, Redman J, Short RV. The correlation between serum and salivary melatonin concentrations and urinary 6-hydroxymelatonin sulphate excretion rates: Two non-invasive techniques for monitoring human circadian rhythmicity. Clin Endocrinol 1987;27:445-52.
7. Wetterberg L. Melatonin in humans physiological and clinical studies. J Neural Transm Suppl 1978;13:289-310.
8. Lang U, Kornemark M, Aubert ML, Paunier L, Sizonenko PC. Radioimmunological determination of urinary melatonin in humans: correlation with plasma levels and typical 24-hour rhythmicity. J Clin Endocrinol Metab 1981;53:645-50.
9. Arendt J, Bojkowski C, Franey C, Wright J, Marks V. Immunoassay of 6-hydroxymelatonin sulfate in human plasma and urine: Abolition of the urinary 24-hour rhythm with atenolol. J Clin Endocrinol Metab 1985; 60:1166-73.
10. Cook MR, Graham C, Kavet R, Stevens RG, Davis S, Kheifets L. Morning urinary assessment of nocturnal melatonin secretion in older women. J Pineal Res 2000;28:41-7.
11. Baskett JJ, Cockrem JF, Antunovich TA. Sulphatoxymelatonin excretion in older people: Relationship to plasma melatonin and renal function. J Pineal Res 1998;24:58-61.
12. Graham C, Cook MR, Kavet R, Sastre A, Smith DK. Prediction of nocturnal plasma melatonin from morning urinary measures. J Pineal Res 1998;24:230-8.
13. Schernhammer ES, Hankinson SE. Light at night: A novel risk factor for cancer in shift workers? Clin Occup Environ Med 2003;3:263-78.
14. Brzezinski A. Melatonin in humans. N Engl J Med 1997;336:186-95.
15. Vijayalaxmi, TC, Reiter RJ, Herman TS. Melatonin: From basic research to cancer treatment clinics. J Clin Oncol 2002;20: 2575-601.
16. Travis RC, Allen DS, Fentiman IS, Key TJ. Melatonin and breast cancer: A prospective study. J Natl Cancer Inst 2004;96:475-82.
17. Rockhill B, Willett WC, Hunter DJ, Manson JE, Hankinson SE, Spiegelman D, et al. Physical activity and breast cancer risk in a cohort of young women. J Natl Cancer Inst 1998;90:1155-60.
18. Schernhammer ES, Rosner B, Willett WC, Laden F, Colditz GA, Hankinson SE. Epidemiology of urinary melatonin in women and its relation to other hormones and night work. Cancer Epidemiol Biomarkers Prev 2004;13:936-43.
19. Adebamowo CA, Cho E, Sampson L, Katan MB, Spiegelman D, Willett WC, et al. Dietary flavonols and flavonol-rich foods intake and the risk of breast cancer. Int J Cancer 2005;114:628-33.
20. Rosner B. Percentage points for a generalized ESD many-outlier procedure. Technometrics 1983;25:165-72.
21. Rosner B, Spiegelman D, Willett WC. Correction of logistic regression relative risk estimates and confidence intervals for random within-person measurement error. Am J Epidemiol 1992;136:1400-13.
22. Tamarkin L, Danforth D, Lichter A, DeMoss E, Cohen M, Chabner B, et al. Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer. Science 1982;216:1003-5.
23. Murphy DL, Garrick NA, Tamarkin L, Taylor PL, Markey SP. Effects of antidepressants and other psychotropic drugs on melatonin release and pineal gland function. J Neural Transm Suppl 1986;21:291 309.
24. Bartsch C, Bartsch H, Jain AK, Laumas KR, Wetterberg L. Urinary melatonin levels in human breast cancer patients. J Neural Transm 1981;52:281-94.
25. Danforth DN, Tamarkin L, Mulvihill JJ, Bagley CS, Lippman ME. Plasma melatonin and the hormone-dependency of human breast cancer. J Clin Oncol 1985;3: 941-8.
26. Lissoni P, Bastone A, Sala R, Mauri R, Rovelli F, Viviani S, et al. The clinical significance of melatonin serum determination in oncological patients and its correlations with GH and PRL blood levels. Eur J Cancer Clin Oncol 1987;23:949-57.
27. Bartsch C, Bartsch H, Fuchs U, Lippert TH, Bellmann O, Gupta D. Stage-dependent depression of melatonin in patients with primary breast cancer. Correlation with prolactin, thyroid stimulating hormone, and steroid receptors. Cancer 1989;64: 426-33.
28. Lissoni P, Crispino S, Barni S, Sormani A, Brivio F, Pelizzoni F, et al. Pineal gland and tumor cell kinetics: Serum levels of melatonin in relation to Ki-67 labeling rate in breast cancer. Oncology 1990;47:275-7.
29. Skene DJ, Bojkowski CJ, Currie JE, Wright J, Boulter PS, Arendt J. 6-sulphatoxymelatonin production in breast cancer patients. J Pineal Res 1990;8:269-76.
30. Falkson G, Falkson HC, Steyn ME, Rapoport BL, Meyer BJ. Plasma melatonin in patients with breast cancer. Oncology 1990;47:401-5.
31. Bartsch C, Bartsch H, Bellmann O, Lippert TH. Depression of serum melatonin in patients with primary breast cancer is not due to an increased peripheral metabolism. Cancer 1991;67:1681-4.
32. Bartsch C, Bartsch H, Karenovics A, Franz H, Peiker G, Mecke D. Nocturnal urinary 6-sulphatoxymelatonin excretion is decreased in primary breast cancer patients compared to age-matched controls and shows negative correlation with tumor-size. J Pineal Res 1997;23:53-8.
33. Hrushesky WJ, Blask DE.ARe: Melatonin and breast cancer: a prospective study. J Natl Cancer Inst 2004;96:888-9.
34. Beck-Friis J, von Rosen D, Kjellman BF, Ljunggren JG, Wetterberg L. Melatonin in relation to body measures, sex, age, season and the use of drugs in patients with major affective disorders and healthy subjects. Psychoneuroendocrinology 1984;9:261-77.
35. Zhang SM. Role of vitamins in the risk, prevention, and treatment of breast cancer. Curr Opin Obstet Gynecol 2004;16:19-25.
36. Welsh J. Vitamin D and breast cancer: Insights from animal models. Am J Clin Nutr 2004;80:1721S-4S.
37. Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, et al. Rotating night shifts and risk of breast cancer in women participating in the Nurses' Health Study. J Natl Cancer Inst 2001;93:1563-8.
38. Girgert R, Bartsch C, Hill SM, Kreienberg R, Hanf V. Tracking the elusive antiestrogenic effect of melatonin: A new methodological approach. Neuro Endocrinol Lett 2003;24: 440-4.
39. Hankinson SE, Willett WC, Manson JE, Colditz GA, Hunter DJ, Spiegelman D, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998;90:1292-9.